Blood Glucose Test Strips Market Forecasts to 2030 – Global Analysis By Type (Thick Film, Electrochemical Films, Thin Film Electrochemical and Optical Strips), Technology (Glucose Dehydrogenase (GDH) and Glucose Oxidase (GOD)), Application (Type 1 Diabete

Blood Glucose Test Strips Market Forecasts to 2030 – Global Analysis By Type (Thick Film, Electrochemical Films, Thin Film Electrochemical and Optical Strips), Technology (Glucose Dehydrogenase (GDH) and Glucose Oxidase (GOD)), Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes and Pre-Diabetes), End User and By Geography

According to Stratistics MRC, the Global Blood Glucose Test Strips Market is accounted for $14.41 billion in 2023 and is expected to reach $25.02 billion by 2030 growing at a CAGR of 8.2% during the forecast period. Thin paper or plastic strips called blood glucose test strips are used to check blood glucose levels and help manage diabetes. The strips are covered in glucose oxidase, which reacts with the blood's glucose to reveal the blood sugar level. These are used by diabetics to monitor their blood glucose levels on a regular basis without having to go to a clinic or a diagnostic lab. In addition, blood glucose test strips are affordable, simple to use, and suitable for daily use.

According to International Diabetes Federation (IDF), the adult diabetes population in 2021 was approximately 537 million, which is expected to increase by 643 million in 2030.

Market Dynamics

Driver

Rising personal disposable income

The rising prevalence of diabetes is one of the main factors anticipated to propel market growth for blood glucose test strips worldwide. Patients prefer to use glucometers for personal use because they are simple to use. The long-term health of diabetics and the primary prevention of chronic diabetic complications both depend on strict glucose control. Patients with diabetes are taught how to manage their daily capillary glucose levels in order to keep them within desired ranges. Blood glucose meters are frequently used by doctors to monitor critically ill patients as well as by diabetic patients to self-manage their disease. Glucometers are also continually upgraded for easier use and greater effectiveness.

Restraint

Lack of awareness

The blood glucose test strip market is likely to face challenges due to patient ignorance of the benefits of improved test strips, unmet clinical needs, and a lack of external funding, which are all limiting market expansion, particularly in developing nations.

Opportunity

Increasing healthcare expenditure and growing urbanization

Blood glucose test strips are still used as they are more reliable and affordable than artificial pancreas systems, despite numerous groundbreaking technological developments that are focused on them. Other factors that are anticipated to contribute to the growth of the global blood glucose test strips market include rising healthcare costs, an aging population, increased consumer awareness of blood glucose test strips, increased government initiatives, and rising disposable income in emerging economies. Additionally, the market is expected to grow as a result of increasing urbanization and an ever-growing population that is leading a more sedentary lifestyle.

Threat

High costs and strict regulations

Strict regulatory requirements could impede growth, and high treatment costs are anticipated to limit market expansion for blood glucose test strips to a large extent during the forecast period. Additionally, the market is anticipated to face challenges due to the high cost of the device when compared to more traditional glucose testing methods.

Covid-19 Impact

The use of blood glucose monitoring equipment has increased during the COVID-19 pandemic, which has affected the demand for test strips. During the COVID-19 pandemic, the demand for and online sales of blood glucose monitoring equipment and supplies, such as test strips, significantly increased. This can be attributed to the rising demand for continuous monitoring of sugar levels in patients and the general population in order to record post-infection symptoms and act as a preventative measure, which is augmenting market growth.

The type 2 diabetes segment is expected to be the largest during the forecast period

During the anticipated period, the type 2 diabetes segment is anticipated to gain significant market share. Patients with Type-2 diabetes must monitor their blood sugar levels to prevent further complications because their blood glucose levels are out of control as a result of their sedentary lifestyles. According to the Centers for Disease Control and Prevention (CDC), type 2 diabetes makes up 90 to 95% of all diagnosed cases of diabetes in adults. Nearly 10% of women have type 2 diabetes identified soon after birth; the remaining women have a 35 to 60% chance of developing the disease over the following 10 to 20 years. The aforementioned factor’s has led to a significant increase in blood glucose test strip demand worldwide.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the highest growth rate during the forecasted period. Since these tests yield results more quickly than traditional laboratory tests, the use of glucose meter kits in hospitals speeds up operational times. SMBG devices are a convenient method, especially for patients who prefer not to use venipuncture methods through syringes or who have hemophobia, as they are minimally invasive and less painful for patients. Additionally, some patients favor visiting hospitals to have their blood sugar levels checked by qualified medical professionals, and this preference is fueling the expansion of this market.

Region with largest share

Owing to its large proportion of health-conscious people and established healthcare industry, the North American region is anticipated to hold a significant market share. North America has a lot of potential for growth in the future due to increased government efforts to combat diabetes and corporate investments to streamline diabetes R&D. In North America, there are currently over 29 million diabetics, and by 2025, that number is expected to rise to 32 million. Additionally, the presence of significant market players in the area has been a major driver of the growth of the blood glucose test strip market in North America over the forecast period.

Region with highest CAGR

Due to the region's increasing need for efficient therapeutic treatment, Asia Pacific is anticipated to be an emerging market for blood glucose test strips during the forecasted period. This growth is primarily the result of the rapidly rising prevalence of diabetes in the area; by 2030, India is expected to have 92.9 million cases. Additionally, the growth is being fueled by the region's rising diabetic population and growing awareness of diabetes management.

Key players in the market

Some of the key players profiled in the Blood Glucose Test Strips Market include Abbott Diabetes Care, ACON Laboratories Inc., Agamatrix Inc., Arkray Inc., Ascensia Diabetes Care, Bayer Diabetes Care, Bionime Corporation, Elektronika, i-SENS, Johnson & Johnson, LifeScan IP Holdings LLC, Nipro Diagnostics, Roche Diagnostics, Rossmax International Ltd, TaiDoc, Trividia Health Inc. and Universal Biosensors.

Key Developments

In November 2022, Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and distributor of the Eversense® Continuous Glucose Monitoring (CGM) System, announces that the Eversense® CGM app has been updated globally to seamlessly integrate with Apple HealthTM. This means that people with diabetes using Eversense CGM Systems will now also have the option to view their glucose data within the Apple Health app, alongside other health metrics on the iPhone’s widely used health and wellbeing platform.

In November 2022, Senseonics and Ascensia Announce a Collaboration with the Nurse Practitioner Group Designed to Expand Patient Access by Providing In-Office and At-Home Insertion Options for Eversense® E3 Continuous Glucose Monitoring System (CGM).

In March 2022, Ministry of Health Canada released Health Network System (HNS) changes to reimbursement of blood glucose test strips under the Ontario Drug Benefit (ODB) Program. The HNS will apply the blood glucose test strip's annual maximum quantity limit based on online claims and papers submitted for reimbursement by ODB-eligible patients.

Types Covered
• Thick Film Electrochemical Films
• Thin Film Electrochemical
• Optical Strips
• Other Types

Technologies Covered
• Glucose Dehydrogenase (GDH)
• Glucose Oxidase (GOD)

Applications Covered
• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes
• Pre-Diabetes

End Users Covered
• Individuals
• Hospitals
• Clinics & Diagnostic Centers
• Other End Users

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026 and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements